Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo
1991

Effect of Bezafibrate on Tumor Growth

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): H.D. Mulligan, M.J. Tisdale

Primary Institution: Pharmaceutical Sciences Institute, Aston University

Hypothesis

The study investigates the effect of the lipid-lowering agent bezafibrate on the growth of the MAC16 tumor in cachectic animals compared to the MAC13 tumor.

Conclusion

Bezafibrate enhances the growth rate of the MAC16 tumor in vivo, likely due to increased lipid availability, while it has no effect on the MAC13 tumor.

Supporting Evidence

  • Bezafibrate significantly enhanced the growth rate of the MAC16 tumor within 2 days of administration.
  • The overall increase in tumor volume in bezafibrate treated animals was three times that of controls.
  • Growth of the MAC13 tumor was unaffected by bezafibrate.

Takeaway

This study found that a drug called bezafibrate can help certain tumors grow faster by increasing the amount of fat available to them.

Methodology

The study used NMRI mice implanted with MAC16 or MAC13 tumors, administering bezafibrate or control and measuring tumor growth and lipid metabolism.

Limitations

The study primarily focuses on two specific tumor types and may not generalize to all tumors.

Participant Demographics

Male NMRI mice, starting weight 24-26 g.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication